Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs has extensive experience in CART structure design and optimization. The following are some anti-EphA2 CAR related products, if you have any needs, please feel free to contact us.
Erythropoietin-producing Hepatocellular receptor tyrosine kinase class A2 (EphA2) is a 130-kDa transmembrane glycoprotein expressed on a variety of tumor tissues. EphA2 interacts with ephrin A-family ligands and mediates several important signaling pathways, which play key roles in regulating various cellular processes of embryonic development, and tumorigenesis. Based on these properties of EphA2, many studies have targeted EphA2 as one of the promising targets for antibody and CAR-T cell development for cancer therapy.
Fig.1 Schematic representation of EphA2 function in cancer.1
Anti-EphA2 CAR-T Expression Test
Creative Biolabs offers a complete series of protein products to detect the expression of anti-CD44v6 CART cells. These protein and cell products have been widely used for the expression test of anti-CD44v6 CAR-T cells.
Meanwhile, we offer several robust and reliable approaches for CAR expression testing, including qPCR, WB, and flow cytometry methods.
Fig.2 WB analysis of EphA2-CAR expression by using CD3ζ antibody.2
Anti-EphA2 CAR-T Proliferation Test
To detect the proliferation capability of CAR-T cells, Creative Biolabs provides a series of optimized methods to evaluate CART cell expansion ability when co-cultured with target tumor cells at different E:T ratios.
Fig.3 Proliferation Testing of different EphA2-CAR-T cells when co-cultured with U251 target cells at 2:1 E:T ratio by flow cytometry using CSFE staining.2
Anti-EphA2 CAR-T Cytokine Release Test
Cytokine release testing is commonly used to assess the performance of CART cells during co-interaction with tumor target cells. Creative Biolabs is committed to providing global customers with comprehensive cytokine release testing services through sensitive methods, such as ELISA, ELISPOT, multiplex cytokine arrays, and intracellularly FACS staining.
Fig.4 IFN-γ secretion assessment of anti-EphA2 CAR-T cells co-cultured with 3 different tumor cells at an E:T ratio of 10:1.2
Anti-EphA2 CAR-T In Vitro Cytotoxicity Assay
The tumor-killing capability of CART cells is an important parameter in CART development. For in vitro cytotoxicity evaluation, we offer a variety of effective and convenient cytotoxicity assays to assist customers' projects.
Luciferase-based cytotoxicity detection assay
Fig.5 In vitro anti-tumor effects assessment of different anti-EphA2 CART cells co-cultured with 3 different tumor cells at indicated E:T ratios by luciferase activity detection.2
RTCA-based cytotoxicity detection assay
Fig.6 In vitro cytotoxicity detection of different anti-EphA2 CART cells co-cultured with 3 different tumor cells at indicated E:T ratios by RTCA assay.2
Anti-EphA2 CAR-T Animal Model Design
Appropriate animal models and experimental design for in vivo efficacy validation will greatly accelerate CART development. Creative Biolabs specializes in providing extensive animal models for customers to choose from, including commonly used CDX models, PDX models, etc. In addition, we are dedicated to providing customized experimental designs according to the specific target.
Fig.7 Schematic diagram of an animal model for anti-EPHA2 CART combined with PD1 blocking therapy.2
Efficacy Test of Anti-EphA2 CAR-T
For in vivo tumor killing analysis, Creative Biolabs provides many optimized mouse models and various detection solutions to speed clients' CART research. At the same time, our in vivo services also cover a variety of phenotypic analyses on cells.
Fig.8 In vivo anti-tumor activity assessment of anti-EphA2 CAR-T cells combined with PD1 blockade in the U251-eGFP-Luc xenograft mouse model.2
Toxicity Evaluation Anti-EphA2 CAR-T
For in vivo toxicity evaluation testing, Creative Biolabs is committed to providing global clients with extensive solutions for the toxicity assessment of CAR-T cells, such as off-target toxicity validation, and phenotypic detection of specific tissues of in vivo models.
For more EphA2 CAR-T related assays, please don't hesitate to contact us directly.
References
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-MV-01LX277 | Anti-EphA2 (XHM268) h(41BB-CD3ζ) CAR, pMMLV | Human | XHM268 | Human | scFv-41BB-CD3ζ | Recombinant Moloney murine leukemia virus (MMLV) retroviral vector | T cell | ||
| CAR-MV-01LX278 | Anti-EphA2 (15) h(41BB-CD3ζ) CAR, pMMLV | Human | 15 | Human | scFv-41BB-CD3ζ | Recombinant Moloney murine leukemia virus (MMLV) retroviral vector | T cell | ||
| CAR-SB-02LX514 | Anti-EphA2 (XHM268) h(ICOS-4-1BB-CD3ζ) CAR, pSBCAR1 | Human | XHM268 | Human | scFv-ICOS-4-1BB-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| CAR-SB-02LX515 | Anti-EphA2 (15) h(ICOS-4-1BB-CD3ζ) CAR, pSBCAR1 | Human | 15 | Human | scFv-ICOS-4-1BB-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| XS-0422-LX30 | Anti-EphA2 (mAb 1) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | mAb 1 | Mouse | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0422-LX31 | Anti-EphA2 (mAb 2) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | mAb 2 | Mouse | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0422-LX32 | Anti-EphA2 (mAb 3) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | mAb 3 | Mouse | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0422-LX33 | Anti-EphA2 (EA2) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | EA2 | Mouse | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0422-LX34 | Anti-EphA2 (B208) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | B208 | Mouse | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0422-LX35 | Anti-EphA2 (B233) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | B233 | Mouse | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0422-LX36 | Anti-EphA2 (hu37.1D7) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | hu37.1D7 | Humanized | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0422-LX37 | Anti-EphA2 (2D6) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 2D6 | Humanized | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0422-LX38 | Anti-EphA2 (D2-1A7) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | D2-1A7 | Humanized | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0422-LX39 | Anti-EphA2 (D2-1B1) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | D2-1B1 | Humanized | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0422-LX40 | Anti-EphA2 (ScFv-a) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | ScFv-a | Humanized | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0422-LX124 | Anti-EphA2 (mAb 1) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | mAb 1 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-0422-LX125 | Anti-EphA2 (mAb 2) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | mAb 2 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-0422-LX126 | Anti-EphA2 (mAb 3) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | mAb 3 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-0422-LX127 | Anti-EphA2 (EA2) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | EA2 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-0422-LX218 | Anti-EphA2 (mAb 1) h(CD28-41BB-CD3ζ) CAR, pSBCAR1 | Human | mAb 1 | Mouse | scFv-CD28-41BB-CD3ζ | Sleeping Beauty (SB) transposon | T cell |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
